Atomwise AI is an AI-powered biopharma company focused on accelerating small-molecule drug discovery and design using artificial intelligence, especially deep convolutional neural networks, with its core being the proprietary AtomNet® platform.
The AtomNet platform can simulate molecular structures and predict the binding affinity between small molecules and protein targets, enabling efficient and accurate screening of virtual libraries containing hundreds of billions of compounds to identify promising drug candidate molecules.
The main advantages are dramatically improved screening efficiency and breadth, shortening the traditional multi-year early discovery timeline to weeks, exploring a broader chemical space, addressing difficult-to-drug targets, and reducing R&D costs.
Its technology has been applied across oncology, neurological disorders, rare diseases, immune and inflammatory diseases, among others, and it collaborates with multiple pharmaceutical companies and academic institutions on related target research.
According to validation data from its AIMS program, the AtomNet platform can screen targets with about 74% accuracy and continually discovers structurally novel compounds, serving as a viable alternative to traditional experimental screening.
Atomwise AI has established broad collaborations with major pharmaceutical and biotech companies and leading research universities worldwide; academic institutions can apply for targeted virtual screening studies through the AIMS program.
Undermind AI is an AI-powered platform for discovering and analyzing scientific literature, capable of reducing weeks of literature research to minutes and delivering efficient, precise AI-powered research support for researchers.
Tempus AI is a precision medicine company that uses artificial intelligence and data platforms to integrate multimodal medical data, delivering data-driven solutions for clinical decision support, medical research and drug development.
